Palatin Technologies, Inc. – LSE:0KF3.L

Add to watchlist

$1.16

+0.09

+9.43%

Market closed

Open in 2 days

-40.11%

month

-40.11%

quarter

-73.83%

year

Market Cap	20.33M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-3.38

Revenue	N/A
EBITDA	-39.05M
Income	-38.91M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Palatin Technologies, Inc. (LSE:0KF3.L): Profit margin
Jun 2022	770.73K	-12.76M	-1656.54%
Mar 2023	1.19M	-6.99M	-585.28%
Jun 2023	1.76M	-10.71M	-608.11%
Mar 2024	0	-8.43M

Palatin Technologies Financials Estimate

Q Y

Palatin Technologies, Inc. (LSE:0KF3.L): Analyst Estimates
2028	111.29M	5.66M	5.09%

Analysts Price target
Financials & Ratios estimates

Palatin Technologies, Inc. (LSE:0KF3.L): Debt to assets
Dec 2022	31976538	15.63M	48.89%
Mar 2023	25608896	16.01M	62.54%
Jun 2023	17939440	15.72M	87.64%
Mar 2024	11406237	9.82M	86.16%

Palatin Technologies, Inc. (LSE:0KF3.L): Cash Flow
Jun 2022	-7.71M	-37.11K	-24.41K
Mar 2023	-1.40M	-116.87K	-25.31K
Jun 2023	-9.60M	-3.04M	1.00M
Mar 2024	-8.60M	0	9.13M

Palatin Technologies alternative data

Palatin Technologies
Employees

Palatin Technologies, Inc. (LSE:0KF3.L): Employee count
Aug 2023	33
Sep 2023	33
Oct 2023	33
Nov 2023	34
Dec 2023	34
Jan 2024	34
Feb 2024	34
Mar 2024	34
Apr 2024	34
May 2024	34
Jun 2024	34
Jul 2024	34

Status	Patent	Filling date	Issue date
Application	Application Orally Active Melanocortin Receptor-4 Compounds Filling date: 9 Mar 2022 Issue date: 30 Jun 2022	9 Mar 2022	30 Jun 2022
Application	Application Melanocortin Receptor-Specific Peptide Formulations and Methods for Gastrointestinal Tract-Specific Delivery Filling date: 22 Sep 2020 Issue date: 24 Mar 2022	22 Sep 2020	24 Mar 2022
Application	Application USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSION Filling date: 21 Jan 2021 Issue date: 22 Jul 2021	21 Jan 2021	22 Jul 2021
Application	Application Orally Active Melanocortin Receptor-4 Compounds Filling date: 17 Mar 2021 Issue date: 1 Jul 2021	17 Mar 2021	1 Jul 2021
Application	Application USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION Filling date: 27 Oct 2020 Issue date: 4 Mar 2021	27 Oct 2020	4 Mar 2021
Application	Application Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy Filling date: 13 Jul 2020 Issue date: 29 Oct 2020	13 Jul 2020	29 Oct 2020
Application	Application Therapies for Obesity, Diabetes and Related Indications Filling date: 19 May 2020 Issue date: 3 Sep 2020	19 May 2020	3 Sep 2020
Grant	Grant Utility: Melanocortin receptor-specific peptide with C-terminal naphthylalanine Filling date: 17 Jan 2018 Issue date: 14 Jul 2020	17 Jan 2018	14 Jul 2020
Grant	Grant Utility: Therapies for obesity, diabetes and related indications Filling date: 3 Oct 2017 Issue date: 26 May 2020	3 Oct 2017	26 May 2020
Grant	Grant Utility: Melanocortin receptor-specific peptides Filling date: 11 Jan 2019 Issue date: 28 Apr 2020	11 Jan 2019	28 Apr 2020

Palatin Technologies
Executives

Insider	Age	Compensation
Dr. Carl Spana (1962) Co-Founder, Pres, Chief Executive Officer & Director	63	$867,620
Mr. Stephen T. Wills CPA, CPA, MST (1957) Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Sec.	68	$797,210
Dr. John K. A. Prendergast (1954) Co-Founder & Independent Non-Executive Chairman	71	$97,500
Burns McClellan Vice President of Investor Relations
Mr. Stephen A. Slusher Esq. Chief Legal Officer

Frequently Asked Questions (FAQ)

What's the price of Palatin Technologies stock today?

One share of Palatin Technologies stock can currently be purchased for approximately $1.16.
When is Palatin Technologies's next earnings date?

Unfortunately, Palatin Technologies's (0KF3.L) next earnings date is currently unknown.
Does Palatin Technologies pay dividends?

No, Palatin Technologies does not pay dividends.
How much money does Palatin Technologies make?

Palatin Technologies has a market capitalization of 20.33M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 7.49% to 4.49M US dollars.
What is Palatin Technologies's stock symbol?

Palatin Technologies, Inc. is traded on the LSE under the ticker symbol "0KF3.L".
What is Palatin Technologies's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Palatin Technologies?

Shares of Palatin Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Palatin Technologies's key executives?
Palatin Technologies's management team includes the following people:
- Dr. Carl Spana Co-Founder, Pres, Chief Executive Officer & Director(age: 63, pay: $867,620)
- Mr. Stephen T. Wills CPA, CPA, MST Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Sec.(age: 68, pay: $797,210)
- Dr. John K. A. Prendergast Co-Founder & Independent Non-Executive Chairman(age: 71, pay: $97,500)
- Burns McClellan Vice President of Investor Relations
- Mr. Stephen A. Slusher Esq. Chief Legal Officer
Is Palatin Technologies founder-led company?

Yes, Palatin Technologies is a company led by its founders Dr. Carl Spana and Dr. John K. A. Prendergast.
How many employees does Palatin Technologies have?

As Jul 2024, Palatin Technologies employs 34 workers.
When Palatin Technologies went public?

Palatin Technologies, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
What is Palatin Technologies's official website?

The official website for Palatin Technologies is palatin.com.
Where are Palatin Technologies's headquarters?

Palatin Technologies is headquartered at Cedar Brook Corporate Center, Cranbury, NJ.
How can i contact Palatin Technologies?

Palatin Technologies's mailing address is Cedar Brook Corporate Center, Cranbury, NJ and company can be reached via phone at +60 9 495 2200.

Palatin Technologies, Inc.

palatin.com

Exchange:

LSE

Full time employees:

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

+60 9 495 2200

Cedar Brook Corporate Center
Cranbury, NJ 08512

:
ISIN: US6960775020
CUSIP: 696077502